Company Overview - SOPHiA GENETICS' Ai platform SOPHiA DDM™ is used by over 800 healthcare institutions globally to analyze complex health data for cancer and rare disorders[7] - The platform analyzes over 350,000 patients annually and has analyzed over 2 million profiles since its inception[8, 21] - The company has invested over $450 million since its inception in its Ai platform[21, 57] Market Trends - The incidence of cancer and rare disorders is increasing worldwide, driving demand for targeted therapies[13] - Healthcare data is rapidly expanding, with 30% of all data generated globally being healthcare-related[16] - The Total Addressable Market (TAM) for Liquid Biopsy is estimated to be over $5 billion[56] Financial Performance - SOPHiA GENETICS' revenue for 2024 was $65.2 million[60] - The company projects revenue between $72 million and $76 million for 2025, representing a year-over-year growth of approximately 10% to 17%[60, 63] - Adjusted EBITDA loss is projected to be between $35 million and $39 million in 2025, compared to $40.2 million in 2024[63] - The company's adjusted gross margin was 72.8% in 2024 and is expected to expand slightly in 2025[63]

Company Overview and Platform - SOPHiA GENETICS's AI platform SOPHiA DDM is used by over 800 healthcare institutions globally [7] - The platform analyzes over 350,000 patients per year and has analyzed over 2 million profiles since inception [8, 21] - The company has invested over $450 million since inception in its AI platform [21] Market Trends and Data Analysis - Healthcare data accounts for 30% of all data generated globally [17] - In 2024, SOPHiA DDM performed over 350,000 genomic analyses, with over 93,000 in Q1 2025 [33] - Total data processed on SOPHiA DDM has seen compounded growth of over 50% since 2021 [46] Financial Performance and Outlook - SOPHiA GENETICS' revenue for 2024 was $65.2 million [68] - The company projects revenue between $72 million and $76 million for 2025, representing approximately 10% to 17% year-over-year growth [71] - Adjusted gross margin was 72.8% in 2024 and is expected to expand slightly in 2025 [71] - The company had a cash balance of $68.5 million as of Q1 2025 [76]

Core Insights - SOPHiA GENETICS reported a strong start to 2025 with a year-over-year revenue growth of 13%, or 15% on a constant currency basis, driven by new business signed in 2024 [3][7] - The company achieved a record adjusted gross margin of 75.7%, up 520 basis points year-over-year, indicating effective cost management and operational efficiency [3][7] - The company continues to focus on long-term growth prospects, particularly in the U.S. market, where revenue from core genomics customers grew over 30% [3][13] Financial Performance - Revenue for Q1 2025 was $17.8 million, reflecting a 13% increase from $15.8 million in Q1 2024 [7][35] - Adjusted EBITDA loss improved by 24% year-over-year to $9.8 million, demonstrating progress towards profitability [7][33] - The company reaffirms its full-year revenue guidance of $72 million to $76 million, representing a growth of approximately 10% to 17% compared to FY 2024 [7][13] Business Highlights - SOPHiA DDM™ platform performed 93,000 analyses in Q1 2025, marking an 11% year-over-year volume growth [8] - The company onboarded 33 new core genomics customers in Q1 2025, up from an average of 23 customers per quarter in 2024 [8] - Significant demand for new applications, including the Liquid Biopsy application MSK-ACCESS®, has led to a healthy pipeline of over 60 identified opportunities [9][10] Market Expansion - The company expanded its collaboration with AstraZeneca to accelerate the deployment of MSK-ACCESS® globally, now involving 30 sponsored institutions [8] - New customers were signed across various geographies, including notable institutions in Belgium, Canada, and Malaysia [8][9] - The U.S. market continues to show strong business growth, with a focus on operational excellence and sustainable growth strategies [10][11]